ALX Oncology Inc.

ALXO · Nasdaq · United States

Share price · ALXO

$0.97-1.11 (-53.36%) 3M

close as of 2026-11-18 · 24h delayed · vol 564K (0.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ALXO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026-13.6%
  2. 2 Nov 2026+12.3%
  3. 16 Oct 2026+6.0%
  4. 15 Oct 2026+11.8%
  5. 14 Oct 2026-8.7%
  6. 13 Oct 2026-22.3%
  7. 24 Sep 2026-7.8%
  8. 6 Aug 2026+9.9%
  9. 9 Jul 2026-11.6%

    Nothing announced by ALXO that day or the session before.

  10. 26 Jun 2026+14.0%

Share of unusual movement by asset

For each asset, the share of ALXO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
CD47Protein / enzyme therapeutic
Multiple MyelomaBreast Cancer
HER2-Positive Breast Cancer
Phase 1
EGFRAntibody–drug conjugate
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
EvorpaceptPhase 2Breast Cancer, Metastatic
Est. primary completion 2027-12 · NCT07007559 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

April 2025Topline resultEvorpaceptPhase 2 ASPEN-03 and ASPEN-04 did not meet their primary endpoints

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$13M$23M+ $116M short-term inv.$18M-$16M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$14M$32M+ $108M short-term inv.$18M-$19M operating cash flowreport ↗
2025-Q3—$17M$24M+ $37M short-term inv.$22M-$17M operating cash flowreport ↗
2025-Q2—$18M$19M+ $60M short-term inv.$26M-$23M operating cash flowreport ↗
2025-Q1—$24M$21M+ $77M short-term inv.$31M-$25M operating cash flowreport ↗
2024-Q3—$26M$16M+ $132M short-term inv.$31M-$25M operating cash flowreport ↗
2024-Q2—$35M$16M+ $141M short-term inv.$39M-$27M operating cash flowreport ↗
2024-Q1—$32M$14M+ $143M short-term inv.$36M-$38M operating cash flowreport ↗
2023-Q3—$46M$20M+ $170M short-term inv.$51M-$31M operating cash flowreport ↗
2023-Q2—$29M$38M+ $175M short-term inv.$34M-$32M operating cash flowreport ↗
2023-Q1—$25M$63M+ $165M short-term inv.$30M-$28M operating cash flowreport ↗
2022-Q3—$29M$49M+ $236M short-term inv.$35M-$31M operating cash flowreport ↗
2022-Q2—$27M$66M+ $247M short-term inv.$33M-$17M operating cash flowreport ↗
2022-Q1—$17M$159M+ $158M short-term inv.$25M-$21M operating cash flowreport ↗
2021-Q3—$18M$385M$25M-$25M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$77M$16M+ $28M short-term inv.$25M-$84M operating cash flowreport ↗

ALX Oncology reported full-year 2025 financials with revenue not disclosed. R&D expenses were $77.0M, down 33.8% YoY from $116.4M. Cash and equivalents stood at $16.44M, while cash, cash equivalents and investments totaled $48.3M as of December 31, 2025. GAAP net loss for the year was $101.7M versus $134.9M in 2024, including a Q4 2025 net loss of $22.8M.

The company guided that existing cash, plus $140.4M in net proceeds from its February 2026 registered offering, should fund operations through 1H 2028. Clinical development for evorpacept and ALX2004 remains on track: ASPEN-09-Breast top-line data are anticipated mid-2027, ALX2004 dose-escalation safety data in 2H 2026, and the full biomarker analysis from the evorpacept-zanidatamab Phase 1b/2 trial was accepted for presentation at ESMO Breast Cancer 2026. Barbara Klencke was also appointed permanent Chief Medical Officer.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$116M$18M+ $110M short-term inv.$34M-$122M operating cash flowreport ↗
2023-FY—$142M$22M+ $160M short-term inv.$40M-$130M operating cash flowreport ↗
2022-FY$0$98M$49M+ $217M short-term inv.$31M-$89M operating cash flowreport ↗
2021-FY$0$60M$364M$21M-$68M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($5.0M), 7 sales ($43K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-17Wong Shelly · SVP, FINANCE AND CAOOpen-market sale573$1.93$1KForm 4
2026-08-17Lettmann Jason · director, CHIEF EXECUTIVE OFFICEROpen-market sale2,230$1.93$4KForm 4
2026-07-01Wong Shelly · SVP, FINANCE AND CAOOpen-market sale1,404$2.04$3KForm 4
2026-04-16Klencke Barbara · Chief Medical OfficerAward / grant (derivative)100,000——Form 4
2026-04-16Knight Jeff E. · Chief Dev & Operating OfficerAward / grant (derivative)800,000——Form 4
2026-03-19Pinto Shelly · SVP, FINANCE AND CAOOpen-market sale903$2.17$2KForm 4
2026-03-19Lettmann Jason · director, CHIEF EXECUTIVE OFFICEROpen-market sale12,311$2.17$27KForm 4
2026-03-03Klencke Barbara · Chief Medical OfficerAward / grant (derivative)700,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 69 reporting institutions held 94.3M shares ($186.7M, 68.2% of shares outstanding).

#InstitutionSharesValue
1RA CAPITAL MANAGEMENT, L.P.13,011,849$26.1M
2TCG Crossover Management, LLC13,011,849$26.1M
3venBio Partners LLC12,884,638$25.8M
4Redmile Group, LLC7,964,188$16.0M
5Blackstone Inc.5,826,544$11.7M
6Driehaus Capital Management LLC5,734,620$11.5M
7VANGUARD CAPITAL MANAGEMENT LLC4,179,736$8.4M
8MARSHALL WACE, LLP3,757,216$7.5M
9Vivo Capital, LLC3,184,713$6.4M
10Almitas Capital LLC3,173,834$6.4M
115AM Venture Management, LLC3,057,325$6.1M
12ORBIMED ADVISORS LLC2,866,256$5.7M
13ADAGE CAPITAL PARTNERS GP, L.L.C.2,000,000$4.0M
14MILLENNIUM MANAGEMENT LLC1,988,559$4.0M
15TWO SIGMA INVESTMENTS, LP1,587,833$3.2M